Cara Therapeutics reported $15.17M in Current Liabilities for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 95.33M 14.04M
Acelrx Pharmaceuticals ACRX:US $ 15.19M 0.36M
Aerie Pharmaceuticals AERI:US $ 108.09M 14.72M
Antares Pharma ATRS:US $ 71.97M 0.17M
Arena Pharmaceuticals ARNA:US $ 64.84M 17.33M
Biodelivery Sciences International BDSI:US $ 63.91M 9.32M
Cara Therapeutics CARA:US $ 15.17M 1.35M
Chugai Pharma 4519:JP Y 244669M 38759M
Depomed DEPO:US $ 116.91M 7.82M
Endo International Ordinary Shares ENDP:US $ 1409.21M 13.72M
Halozyme Therapeutics HALO:US $ 114.25M 6.83M
Horizon Pharma HZNP:US $ 852.81M 78.97M
JAZZ PHA JAZZ:US $ 880.59M 128.5M
Neurocrine Biosciences NBIX:US $ 212.9M 22.9M
Pacira Pharmaceuticals PCRX:US $ 228.69M 3.39M
Pain Therapeutics PTIE:US $ 4.64M 1.99M
Redhill Biopharma RDHL:US $ 79.17M 12.54M
Revance Therapeutics RVNC:US $ 58.25M 7.41M
Supernus Pharmaceuticals SUPN:US $ 283.45M 42.64M
Teva Pharmaceutical Industries TEVA:US $ 12691M 602M
Vanda Pharmaceuticals VNDA:US $ 71.99M 10.2M